Cardiovascular Adverse Event Risk Following a COPD Exacerbation
In the first 30 days following an exacerbation of chronic obstructive pulmonary disease, there is an increased risk of cardiovascular adverse events.
CHEST 2020 COPD In-Depth
Complete Coverage
Acute COPD Exacerbations May Be Linked to Higher HbA1c Levels
Patients with chronic obstructive pulmonary disease (COPD) who have higher levels of HbA1c are at increased risk for hospital admission for acute exacerbations.
Switch to Extra-Fine Inhaled Triple Therapy Improves Regional Ventilation to Small Airways in COPD
Switching from non-extra fine multi-inhaler triple therapy to single-inhaler extra-fine inhaled triple therapy improved regional ventilation to the small airways in patients with COPD.
Inhaled Corticosteroid Therapy May Reduce Lung Function Decline in COPD
The adjusted rate of decline in predose trough FEV1 during 52 weeks in theResearchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with inhaled corticosteroid-containing therapies vs glycopyrrolate/formoterol fumarate metered dose inhaler.
Revefenacin Plus Formoterol Via Nebulization Improves Lung Function Response in COPD
Once-daily revefenacin when administered via a jet nebulizer with formoterol was well tolerated and associated with greater lung function response compared with formoterol alone in patients with COPD.
Mechanically Ventilated Patients With COPD May Benefit From Early Tracheostomy
Researchers conducted a retrospective analysis of patients with COPD who were hospitalized and mechanically ventilated.
Want to read more?
Please login or register first to view this content.